Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02358395
Other study ID # D8808001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 2015
Est. completion date November 2017

Study information

Verified date April 2022
Source Sumitomo Pharma Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multicenter, phase 1 study of BBI608 in combination with Sorafenib. This study population is adult Japanese patients with advanced hepatocellular carcinoma in Sorafenib combination therapy.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date November 2017
Est. primary completion date November 2017
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Histologically or diagnosed imaging with hepatocellular carcinoma, and not indicated with a)-d) . 1. Radiofrequency ablation therapy (RFA) 2. Local therapy [such as percutaneous transhepatic ethanol injection therapy (PEIT), Microwave coagulation therapy (MCT)] 3. Transcatheter arterial embolization (TAE) 4. Transcatheter arterial chemoembolization (TACE) - = 20 years of age. - Not treatment with systemic chemotherapy. - Signed written informed consent must be obtained and documented. - Life expectancy = 3 months. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Must be Child Pugh Class A. - Hemoglobin = 8.5 mg/dl. - Absolute neutrophil count = 1.5 x 10^9 /L. - Platelets = 75 x 10^9/L. - Creatinine = 1.5 x ULN. - Total Bilirubin = 3.0 mg/dl. - Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) = 5.0 x the upper limit of normal (ULN). - Females of childbearing potential must have a negative serum pregnancy test. - Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI608 dose. Exclusion Criteria: - Have had any t a)-i) treatment less than 28 days prior to beginning the enrolment. 1. Radiation therapy 2. Hormone therapy 3. Immune therapy 4. Hyperthermia 5. Surgical procedure 6. Local therapy (such as RFA, PEIT, MCT) 7. TAE 8. TACE 9. other anti- tumour treatment - Have had a brain metastases with a symptom or requiring treatment. - Have had coinstantaneous active multiple cancers. - Have had a carcinomatous pleural effusion, ascites, or cardiac effusion requiring treatment. - Esophageal varix requiring treatment. - Patient of pregnancy or possibility of pregnancy, and planning breastfeeding by the end of BBI608 administration after 30days. - Crohns disease, ulcerative colitis, or historical surgery of extensively small intestine resection. - Unable or unwilling to swallow BBI608 capsules or Sorafenib tablets. - Uncontrolled inter-current illness (such as Grade 3active infection, or serious respiratory disease). - HIV infection. - Abnormal ECGs which are clinically significant within 28 days before enrolment. - Patients who are New York Heart Association (NYHA) functional classes III, or IV, or unstable angina. - Patients newly expressing angina within three months before the enrolment. - Have had myocardial infarction within six months before the enrolment. - Administrating with antiarrhythmic drug. - Have received other investigational products or post-marketing investigational products within 4 weeks of the first dose of BBI608. - Prior treatment with BBI608. - Hypersensitivity to Sorafenib or any other component of Sorafenib. - Ineligible for participation in the study in the opinion of the Investigators.

Study Design


Intervention

Drug:
BBI608
Administered continuously twice daily with doses separated by 9-15 hours.
Sorafenib
Sorafenib 400 mg twice daily (800 mg total daily dose).

Locations

Country Name City State
Japan 4 Sites Tokyo,etc

Sponsors (1)

Lead Sponsor Collaborator
Sumitomo Pharma Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of safety and tolerability of BBI608 given in combination with Sorafenib by reporting of adverse events and serious adverse events. 7 month
Primary Assessment of dose-limiting toxicities (DLTs). 29 days
Primary Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib. On day 1: Prior to BBI608 dosing and 2,4,6,8,10,12 and 24 hours after the first dose. On day 29: Prior to BBI608 dosing and 2,4,6,8,10,12 and 24 hours after the first dose.
Secondary Assessment of the preliminary anti-tumour activity. Anti-tumour activity is assessed every 8 weeks from the first dose of BBI608 after the last dose of BBI608.The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with hepatocellular carcinoma. Approximately 7 months
Secondary Progression Free Survival The time the participant stays on study until progression will be measured and recorded. Approximately 7 month
Secondary Overall Survival Participants follow-up for overall survival will occur. Maximum follow-up time is 1 year after the initial administration of the last subject. Approximately 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2